Ensign Peak Advisors’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$481K Hold
7,296
﹤0.01% 969
2025
Q4
$464K Sell
7,296
-13,200
-64% -$821K ﹤0.01% 977
2025
Q3
$1.13M Sell
20,496
-183,450
-90% -$7.56M ﹤0.01% 979
2025
Q2
$6.74M Buy
203,946
+172,150
+541% +$5.99M 0.01% 575
2025
Q1
$1.28M Sell
31,796
-265,039
-89% -$12.2M ﹤0.01% 1114
2024
Q4
$14M Sell
296,835
-165,001
-36% -$8.57M 0.02% 388
2024
Q3
$24.4M Sell
461,836
-1,595
-0.3% -$88.9K 0.04% 289
2024
Q2
$25.1M Buy
463,431
+39,172
+9% +$2.36M 0.05% 271
2024
Q1
$29.7M Sell
424,259
-1,604
-0.4% -$124K 0.05% 253
2023
Q4
$35.6M Hold
425,863
0.07% 231
2023
Q3
$12.5M Buy
425,863
+74,694
+21% +$2.49M 0.03% 336
2023
Q2
$11.5M Hold
351,169
0.02% 387
2023
Q1
$12.4M Buy
351,169
+8,400
+2% +$343K 0.03% 369
2022
Q4
$15.7M Buy
342,769
+59,400
+21% +$2.56M 0.04% 332
2022
Q3
$13.7M Buy
283,369
+45,600
+19% +$2.19M 0.03% 321
2022
Q2
$9.34M Buy
237,769
+69,904
+42% +$2.81M 0.02% 396
2022
Q1
$6.18M Buy
167,865
+9,960
+6% +$354K 0.01% 528
2021
Q4
$7.2M Sell
157,905
-40,650
-20% -$1.57M 0.01% 560
2021
Q3
$7.1M Sell
198,555
-4,000
-2% -$118K 0.01% 519
2021
Q2
$4.01M Buy
202,555
+37,010
+22% +$869K 0.01% 740
2021
Q1
$3.85M Buy
165,545
+91,145
+123% +$1.95M 0.01% 743
2020
Q4
$1.55M Sell
74,400
-49,022
-40% -$896K ﹤0.01% 1203
2020
Q3
$2.67M Buy
123,422
+49,022
+66% +$1.15M 0.01% 822
2020
Q2
$1.75M Hold
74,400
﹤0.01% 1044
2020
Q1
$877K Buy
74,400
+8,500
+13% +$108K ﹤0.01% 1216
2019
Q4
$699K Buy
+65,900
New +$677K ﹤0.01% 1456

Other funds holding CYTK